Fundraising FoxNovartis Venture Fund — 2024 Investments
5 investments dated 2024 · listed companies and verified rows first · show all
Aravax is a clinical-stage biotechnology company developing next-generation immunotherapies to treat food allergies.
BiotechHealthtechMedical DevicesMelbourne, AU
Sara Prickett(Co-founder)in
Co-investorsBrandon CapitalBreakthrough VictoriaTenmileUniSeed Pty Ltd.
RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.
BiotechDigital HealthMedical DevicesBasel, CH
Botond Roska(Researcher (M.D., Ph.D.))Bence György(IOB Assistant Professor & Head of Clinical Translation)inKatherine High(CEO)in
Co-investorsARCH Venture PartnersBioGeneration VenturesF-Prime CapitalGV (Google Ventures)
Averna Therapeutics is a biotechnology company developing therapeutics.
BiotechDeep TechHealthtechMedical DevicesWatertown, US
Richard Morris(Chief Financial Officer)inThomas M. Barnes(CEO & Board Member)
BoardRoy Amariglio(Director)Nick Olsen(Director)inStephen Squinto(Director)inMichal Silverberg(Director)in
Co-investorsDeep InsightDelos CapitalOrbiMedARC VENTURESInsight Partners
Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones.
BiotechHealthtechMedical DevicesOss, NL
Renato Chirivi(Co-founder (former CSO))in
BoardPaul Peter Tak(Chair of the Board)
Co-investorsBioGeneration VenturesPureos BioventuresSeventure PartnersForbionJohnson & Johnson Innovation – JJDCBOM+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
FundaMental Pharma
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.